Enanta Pharmaceuticals (ENTA) Change in Account Payables (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Change in Account Payables data on file, last reported at $2.5 million in Q1 2026.

• Quarterly Change in Account Payables rose 183.85% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $399000.0 (up 1230.0% YoY) and the FY2025 annual result came in at -$1.3 million, down 216.67% from the prior year.
• Change in Account Payables rose to $2.5 million in Q1 2026, from -$63000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $6.6 million in Q1 2023 to a low of -$5.1 million in Q2 2022.
• A 5-year average of -$201882.4 and a median of -$686000.0 in 2022 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2022 — Change in Account Payables tumbled 2923.33% — and 2023, when it jumped 854.23%.
• Tracing ENTA's Change in Account Payables over 5 years: stood at -$686000.0 in 2022, then jumped by 854.23% to $5.2 million in 2023, then sank by 103.25% to -$168000.0 in 2024, then jumped by 62.5% to -$63000.0 in 2025, then jumped by 4033.33% to $2.5 million in 2026.
• The last three Change in Account Payables figures came in at $2.5 million (Q1 2026), -$63000.0 (Q4 2025), and -$723000.0 (Q3 2025), per Business Quant data.